Celcuity disclosed that it is awaiting FDA review for a second manufacturing site after the company’s recently approved cancer drug’s commercial rollout progressed more slowly than investors expected. The update focuses on production readiness and regulatory permitting steps tied to scaling supply. The company’s decision to wait for FDA review highlights the operational dependence of commercialization timelines on manufacturing oversight and facility approvals. For precision diagnostics and imaging-adjacent product models, the pace of expansion can directly affect revenue ramp trajectories and customer access. Celcuity’s statement provides a nearer-term catalyst signal: progress in the FDA evaluation process for the additional site could influence future throughput while reducing reliance on a single factory.